{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:15:27Z","timestamp":1787030127136,"version":"build-2736575974"},"reference-count":91,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein\u2013Barr virus, cytomegalovirus, and respiratory viruses. With the emergence of SARS-CoV-2, new and existing drugs have been intensively evaluated for their potential as COVID-19 medication. Due to its potent immunomodulatory properties, inosine pranobex, an orally administered drug with pleiotropic effects, can, during early treatment, alter the course of the disease. We describe the action of inosine pranobex in the body and give an overview of existing evidence collected to support further efforts to study this drug in a rigorous clinical trial setup.<\/jats:p>","DOI":"10.3390\/v13112246","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T21:39:07Z","timestamp":1636493947000},"page":"2246","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-4197","authenticated-orcid":false,"given":"Ji\u0159\u00ed","family":"Beran","sequence":"first","affiliation":[{"name":"Department for Tropical, Travel Medicine and Immunization, Institute of Postgraduate Health Education, 100 05 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"\u0160pajdel","sequence":"additional","affiliation":[{"name":"Department of Psychology, Faculty of Philosophy and Arts, Trnava University, 918 43 Trnava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Sl\u00edva","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Third Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1473-3099(21)00202-4","article-title":"SARS-CoV-2 incidence and vaccine escape","volume":"21","author":"Thompson","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Inchingolo, A., Inchingolo, A., Bordea, I., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G., and Isacco, C. (2021). SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs. Microorganisms, 9.","DOI":"10.3390\/microorganisms9040793"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1016\/j.vaccine.2020.09.084","article-title":"Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey","volume":"38","author":"Goldman","year":"2020","journal-title":"Vaccine"},{"key":"ref_4","unstructured":"Odone, A., Bucci, D., Croci, R., Ricc\u00f2, M., Affanni, P., and Signorelli, C. (2020). Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts. Acta Biomed., 91."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tichop\u00e1d, A., Pecen, L., and Sedl\u00e1k, V. (2021). Could the new coronavirus have infected humans prior November 2019?. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248255"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Bernal","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Stowe, J., Andrews, N., Gower, C., Gallagher, E., Utsi, L., Simmons, R., Thelwall, S., Tessier, E., Groves, N., and Dabrera, G. (2021). Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. Public Health Engl., Available online: https:\/\/khub.net\/web\/phe-national\/public-library\/-\/document_library\/v2WsRK3ZlEig\/view\/479607266."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Griffin, S. (2021). COVID-19: Fully vaccinated people can carry as much delta virus as unvaccinated people, data indicate. BMJ, 374.","DOI":"10.1136\/bmj.n2074"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-00107-1","article-title":"Battling COVID-19: Using old weapons for a new enemy","volume":"6","author":"Kumar","year":"2020","journal-title":"Trop. Dis. Travel Med. Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Inchingolo, A., Inchingolo, A., Bordea, I., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G., and Isacco, C. (2021). SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. Microorganisms, 9.","DOI":"10.3390\/microorganisms9030525"},{"key":"ref_13","first-page":"453","article-title":"Impact of COVID-19 Pandemic on Healthcare Professionals and Oral Care Operational Services: A Systemic Review","volume":"14","author":"Bordea","year":"2021","journal-title":"Heal. Policy Politi-Sante"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/JIR.S282213","article-title":"Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review","volume":"14","author":"Hanna","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/ppul.24991","article-title":"Clinical characteristics of COVID-19 in children: A systematic review","volume":"55","author":"Yasuhara","year":"2020","journal-title":"Pediatr. Pulmonol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pormohammad, A., Ghorbani, S., Baradaran, B., Khatami, A., Turner, R.J., Mansournia, M.A., Kyriacou, D.N., Idrovo, J.-P., and Bahr, N.C. (2020). Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61,742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis. Microb. Pathog., 147.","DOI":"10.1016\/j.micpath.2020.104390"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/bib\/bbaa288","article-title":"A review on drug repurposing applicable to COVID-19","volume":"22","author":"Dotolo","year":"2021","journal-title":"Brief. Bioinform."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sultana, J., Crisafulli, S., Gabbay, F., Lynn, E., Shakir, S., and Trifir\u00f2, G. (2020). Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.588654"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Pawar, A.Y. (2020). Combating devastating COVID-19 by drug repurposing. Int. J. Antimicrob. Agents, 56.","DOI":"10.1016\/j.ijantimicag.2020.105984"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Jang, W.D., Jeon, S., Kim, S., and Lee, S.Y. (2021). Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc. Natl. Acad. Sci. USA, 118.","DOI":"10.1073\/pnas.2024302118"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12519-020-00354-4","article-title":"Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: A single center\u2019s observational study","volume":"16","author":"Sun","year":"2020","journal-title":"World J. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","article-title":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China","volume":"46","author":"Ruan","year":"2020","journal-title":"Intensive Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coviro.2015.10.008","article-title":"Roles of natural killer cells in antiviral immunity","volume":"16","author":"Waggoner","year":"2015","journal-title":"Curr. Opin. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijid.2020.04.086","article-title":"Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis","volume":"96","author":"Zhao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40560-020-00453-4","article-title":"Lymphopenia in severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis","volume":"8","author":"Huang","year":"2020","journal-title":"J. Intensive Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Zheng, Q., Li, Y.-Z., Huang, G., Wu, W., Dong, S.-Y., and Xu, Y. (2021, August 30). Mortality of COVID-19 Is Associated with Cellular Immune Function Compared to Immune Function in the Chinese Han Population. Available online: https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.08.20031229v2.","DOI":"10.1101\/2020.03.08.20031229"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","article-title":"Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study","volume":"5","author":"Tan","year":"2020","journal-title":"Signal. Transduct. Target Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jafarzadeh, A., Jafarzadeh, S., Nozari, P., Mokhtari, P., and Nemati, M. (2021). Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms. Scand. J. Immunol., 93.","DOI":"10.1111\/sji.12967"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","article-title":"Breadth of concomitant immune responses prior to patient recovery: A case report of non-severe COVID-19","volume":"26","author":"Thevarajan","year":"2020","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s13063-020-04389-w","article-title":"Two Randomized Controlled Trials of Bacillus Calmette-Gu\u00e9rin Vaccination to reduce absenteeism among health care workers and hospital admission by elderly persons during the COVID-19 pandemic: A structured summary of the study protocols for two randomised controlled trials","volume":"21","author":"Doesschate","year":"2020","journal-title":"Trials"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/thoraxjnl-2020-216243","article-title":"COVID-19, immunothrombosis and venous thromboembolism: Biological mechanisms","volume":"76","author":"Loo","year":"2021","journal-title":"Thorax"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/iub.2356","article-title":"Bacterial co-infections with SARS-CoV-2","volume":"72","author":"Mirzaei","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_36","first-page":"12593","article-title":"Possible treatment and strategies for COVID-19: Review and assessment","volume":"24","author":"Trivedi","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.4049\/jimmunol.121.3.1184","article-title":"Inosiplex, a stimulating agent for normal human T cells and human leukocytes","volume":"121","author":"Wybran","year":"1978","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Wybran, J., and Appelboom, T. (1984). Isoprinosine (Inosiplex): Immunological and Clinical Effects. Immunomodulation, Springer International Publishing.","DOI":"10.1007\/978-1-4615-9358-4_25"},{"key":"ref_39","first-page":"497","article-title":"Isoprinosine in the treatment of genital warts","volume":"12","author":"Robins","year":"1988","journal-title":"Cancer Detect. Prev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1471-0528.2006.01041.x","article-title":"Rigopoulos, D. Oral inosiplex in the treatment of cervical condy-lomata acuminata: A randomised placebo-controlled trial","volume":"113","author":"Georgala","year":"2006","journal-title":"BJOG"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0192-0561(85)90025-6","article-title":"Isoprinosine enhances the activation of sensitized lymphocytes by Epstein-Barr virus antigens","volume":"7","author":"Sundar","year":"1985","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-3083.1990.tb03206.x","article-title":"Effects of Isoprinosine Treatment of HIV-Positive Patients on Blood Mononuclear Cell Subsets, NK- and T-Cell Function, Tumour Necrosis Factor, and Interleukins 1, 2, and 6","volume":"32","author":"Pedersen","year":"1990","journal-title":"Scand. J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0192-0561(86)90074-3","article-title":"Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production","volume":"8","author":"Hadden","year":"1986","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/0192-0561(91)90055-C","article-title":"Effect of isoprinosine on IL-2, IFN-\u03b3 and IL-4 production in vivo and in vitro","volume":"13","author":"Milano","year":"1991","journal-title":"Int. J. Immunopharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/jir.2009.0057","article-title":"Isoprinosine Affects Serum Cytokine Levels in Healthy Adults","volume":"30","author":"Petrova","year":"2010","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1515\/acph-2015-0015","article-title":"Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes","volume":"65","author":"Lasek","year":"2015","journal-title":"Acta Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1139\/m72-224","article-title":"The anti-viral activity of isoprinosine","volume":"18","author":"Gordon","year":"1972","journal-title":"Can. J. Microbiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00000441-197302000-00005","article-title":"Antiviral activity of isoprinosine in vitro and in vivo","volume":"265","author":"Chang","year":"1973","journal-title":"Am. J. Med. Sci."},{"key":"ref_49","first-page":"1095","article-title":"The in vitro anti-viral activity of isoprinosine on simian rotavirus (SA-11)","volume":"22","author":"Linhares","year":"1989","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1007\/s12325-019-00995-6","article-title":"Inosine Pranobex: A Key Player in the Game against a Wide Range of Viral Infections and Non-Infectious Diseases","volume":"36","author":"Sliva","year":"2019","journal-title":"Adv. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/1346-8138.12845","article-title":"Multicenter randomized study of inosine pranobex versus acyclovir in the treatment of recurrent herpes la-bialis and recurrent herpes genitalis in Chinese patients","volume":"42","author":"You","year":"2015","journal-title":"J. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Galli, M., Lazzarin, A., Moroni, M., and Zanussi, C. (1984). Treatment of Recurrent Viral Infectious Diseases by Methisoprinol. Immunomodulation, Springer.","DOI":"10.1007\/978-1-4615-9358-4_27"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(82)90300-2","article-title":"Inosiplex in recurrent herpes simplex infections","volume":"2","author":"Galli","year":"1982","journal-title":"Lancet"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0140-6736(85)92239-1","article-title":"Inosine Pranobex in Mucocutaneous Herpes","volume":"325","author":"Talbot","year":"1985","journal-title":"Lancet"},{"key":"ref_55","first-page":"681","article-title":"Suppression of recurrent genital herpes by inosine pranobex: Effects of episodic and continuous treatment","volume":"43","author":"Byrne","year":"1988","journal-title":"Curr. Ther. Res.-Clin. Exp."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/sti.65.2.103","article-title":"Suppression of frequently recurring genital herpes: Acyclovir v inosine pranobex","volume":"65","author":"Mindel","year":"1989","journal-title":"Sex. Transm. Infect."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/sti.68.5.312","article-title":"Acyclovir vs isoprinosine (immunovir) for suppression of recurrent genital herpes simplex infection","volume":"68","author":"Kinghorn","year":"1992","journal-title":"Sex. Transm. Infect."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Huttenlocher, P.R., and Mattson, R.H. (1979). Isoprinosine in subacute sclerosing panencephalitis. Neurology, 29.","DOI":"10.1212\/WNL.29.6.763"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.410070216","article-title":"Isoprinosine treatment in 18 patients with subacute sclerosing panencephalitis: A controlled study","volume":"7","author":"Haddad","year":"1980","journal-title":"Ann. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archneur.1979.00500420084012","article-title":"Inosiplex in the Treatment of Subacute Sclerosing Panencephalitis","volume":"36","author":"Silverberg","year":"1979","journal-title":"Arch. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(82)92097-9","article-title":"Inosiplex Therapy in Subacute Sclerosing Panencephalitis","volume":"319","author":"Jones","year":"1982","journal-title":"Lancet"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3476(82)80143-1","article-title":"The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis","volume":"101","author":"DuRant","year":"1982","journal-title":"J. Pediatr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.48.2.526","article-title":"Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular \u03b1-interferon","volume":"482","author":"Anlar","year":"1997","journal-title":"Neurology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1177\/088307389801301106","article-title":"\u03b2-Interferon Plus Inosiplex in the Treatment of Subacute Sclerosing Panencephalitis","volume":"13","author":"Anlar","year":"1998","journal-title":"J. Child Neurol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Yalaz, K., Anlar, B., Oktem, F., Aysun, S., Ustacelebi, S., Gurcay, O., Gucuyener, K., and Renda, Y. (1992). Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis. Neurology, 42.","DOI":"10.1212\/WNL.42.3.488"},{"key":"ref_66","first-page":"626","article-title":"Comparison of the results of the treatment of patients with SSPE using various immunomodulating preparations","volume":"25","author":"Sobczyk","year":"1991","journal-title":"Neurol. Neurochir. Polska"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0387-7604(93)90120-W","article-title":"Combined oral isoprinosine-intraventricular \u03b1-interferon therapy for subacute sclerosing panencephalitis","volume":"15","author":"Gascon","year":"1993","journal-title":"Brain Dev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/7.4.389","article-title":"Effect of inosiplex (isoprinosine) on induced human in-fluenza infection","volume":"7","author":"Khakoo","year":"1981","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1965-5","article-title":"Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: Analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study","volume":"16","author":"Beran","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.1977.tb21946.x","article-title":"Therapeutic efficacy of inosiplex (isoprinosine\u00ae) in rhinovirus infection","volume":"284","author":"Waldman","year":"1977","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_71","first-page":"155","article-title":"Immunorestorative properties of isoprinosine in the treatment of patients at high risk of developing ARC or AIDS","volume":"24","author":"Bekesi","year":"1987","journal-title":"J. Clin. Lab. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0090-1229(86)90218-7","article-title":"A double-blind clinical trial of the effects of inosine pranobex in immunodepressed patients with prolonged generalized lymphadenopathy","volume":"39","author":"Wallace","year":"1986","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1128\/AAC.37.6.1227","article-title":"Inhibition of Pneumocystis carinii dihydropteroate synthetase by para-acetamidobenzoic acid: Possible mechanism of action of isoprinosine in human immunodeficiency virus infection","volume":"37","author":"Kovacs","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_74","unstructured":"World Health Organization (2021, September 05). Influenza: BRaVe Call to Action. Available online: http:\/\/www.who.int\/influenza\/patient_care\/clinical\/call_to_action\/en\/."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imm.12854","article-title":"The biology of natural killer cells during sepsis","volume":"153","author":"Guo","year":"2017","journal-title":"Immunology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0065-2776(08)60664-1","article-title":"Biology of Natural Killer Cells","volume":"47","author":"Trinchieri","year":"1989","journal-title":"Adv. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coviro.2020.07.003","article-title":"Natural killer cell responses to emerging viruses of zoonotic origin","volume":"44","author":"Sun","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/35095564","article-title":"Natural killer cells, viruses and cancer","volume":"1","author":"Cerwenka","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1146\/annurev-immunol-032712-100001","article-title":"Control of Human Viral Infections by Natural Killer Cells","volume":"31","author":"Jost","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural Killer Cell Signaling Pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.intimp.2016.11.023","article-title":"Inosine Acedoben Dimepranol promotes an early and sustained increase in the natural killer cell component of circulating lymphocytes: A clinical trial supporting anti-viral indications","volume":"42","author":"Ahmed","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Ma, Y., Li, X., and Kuang, E. (2016). Viral Evasion of Natural Killer Cell Activation. Viruses, 8.","DOI":"10.3390\/v8040095"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.cdd.4402170","article-title":"NK cells at the interface between innate and adaptive immunity","volume":"15","author":"Moretta","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molimm.2004.07.034","article-title":"Activation of NK cell cytotoxicity","volume":"42","author":"Smyth","year":"2005","journal-title":"Mol. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000328005","article-title":"Immunosenescence of Human Natural Killer Cells","volume":"3","author":"Gayoso","year":"2011","journal-title":"J. Innate Immun."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.arr.2013.04.003","article-title":"The impact of ageing on natural killer cell function and potential consequences for health in older adults","volume":"12","author":"Hazeldine","year":"2013","journal-title":"Ageing Res. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/eji.201847948","article-title":"Inosine pranobex enhances human NK cell cytotoxicity by inducing metabolic activation and NKG2D ligand expression","volume":"50","author":"McCarthy","year":"2020","journal-title":"Eur. J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Beran, J., \u0160pajdel, M., Katzerov\u00e1, V., Holou\u0161ov\u00e1, A., Maly\u0161, J., Finger Rouskov\u00e1, J., and Sl\u00edva, J. (2020). Inosine pranobex significantly decreased the case-fatality rate among PCR positive elderly with SARS-CoV-2 at three nursing homes in the Czech Republic. Pathogens, 9.","DOI":"10.3390\/pathogens9121055"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ageing\/afaa220","article-title":"Asymptomatic carriage rates and case fatality of SARS-CoV-2 infection in residents and staff in Irish nursing homes","volume":"50","author":"Kennelly","year":"2021","journal-title":"Age Ageing."},{"key":"ref_91","first-page":"41","article-title":"Estudio experimental: Manejo del metisoprinol en pacientes con COVID-19","volume":"24","author":"Borges","year":"2020","journal-title":"Univ. Cienc. Tecnol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/11\/2246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:27:58Z","timestamp":1760167678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/11\/2246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":91,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["v13112246"],"URL":"https:\/\/doi.org\/10.3390\/v13112246","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]}}}